Table 1 Distribution of antimicrobial use, individually or by class, expressed in percentages, DOT and LOT per 1000 patient-days (pd), and the DOT/LOT ratio, by hospital ward, 2018

Use of antimicrobials (%)

38.0^a

42.0^b

62.0^c(a)

64.0^d(a)

86.0^e(ab)

Number of prescriptions (%)

 First-generation cephalosporins IV/PO

49.4^a(bce)

3.9^b

1.4^c

34.5^d(bc)

9.6^e

 Fluoroquinolones IV/PO

20.5^a

14.2^b

11.2^c

3.6^d(abe)

13.7^e

 Carbapenems IV

1.7^a

11.6^b(a)

8.8^c

6.3^d

19.6^e(ad)

 Third-generation cephalosporins IV

6.5^a

14.8^b(ae)

8.5^c

9.2^d

4.1^e

 Metronidazole IV/PO

10.1^a

5.8^b

1.7^c(ae)

6.3^d

11.3^e

 Cefepime IV

0.8^a

10.3^b(a)

15.6^c(a)

6.0^d

7.2^e

 Clindamycin IV

9.1

7.1

5.1

2.1

7.6

 Antifungals IV/PO

0.2^a

7.1^b(a)

16.0^c(ad)

4.5^d

6.9^e

 Glycopeptides IV

1.1^a

6.5^b

3.4^c

3.0^d

10.7^e(acd)

 Azithromycin IV/PO

0^a

2.6^b

9.5^c(abe)

6.3^d(a)

1.7^e

 Penicillins¹ IV/PO

0.2^a

10.3^b(ae)

3.4^c

8.3^d(ae)

1.0^e

 Co-trimoxazole IV/PO

0^a

3.2^b

10.9^c(abe)

3.6^d(a)

3.1^e

 Aminoglycosides IV

0.4^a

2.6^b

4.4^c

6.5^d(a)

3.4^e

ID LOT/1000pd

300^a

262^b

470^c(ab)

382^d(b)

753^e(abcd)

ID DOT/1000pd

 Fluoroquinolones IV/PO

108^a

57^b

71^c

28^d(ae)

147^e

 First-generation cephalosporins IV/PO

123^a(bc)

6^b

6^c

94^d(bc)

73^e(bc)

 Carbapenems IV

11^a

43^b

84^c(a)

40^d

368^e(abd)

 Third-generation cephalosporins IV

43

57

64

61

35

 Cefepime IV

8^a(ce)

32^b

95^c

47^d

114^e

 Metronidazole IV/PO

56^a

12^b(e)

8^c(ade)

59^d

119^e

 Antifungals IV/PO

1^a(ce)

24^b

83^c

40^d

118^e

 Co-trimoxazole IV/PO

0^a

4^b(c)

121^c(ab)

25^d

72^e(a)

 Clindamycin IV

47

28

37

12

73

 Glycopeptides IV

8^a

25^b

36^c

10^d

183^e(abcd)

 Aminoglycosides IV

6

16

32

34

83

 Penicillins¹ IV/PO

1^a

35^b(a)

18^c

38^d(ae)

13^e

 Azithromycin IV/PO

0^a(cd)

10^b(c)

40^c

31^d

23^e

ID DOT/LOT ratio

1.4^a

1.3^b

1.5^c

1.4^d

2.0^e(abcd)